DISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed Financing
Transformative surfaceome discovery technology enables a…
Biocomposites expands its international presence by opening new sales and distribution office in Italy
Biocomposites SRL will support sales of STIMULAN, NanoBone,…
DelSiTech Announces Closing of EUR 10 Million Financing Round to Advance its Silica-Based Drug Delivery Technology Platform
New investment from DRW Venture Capital LLC and Tolmar International…
Futura Medical extends collaboration with Cooper Consumer Health
Futura Medical plc (AIM: FUM) ("Futura" or the "Company"), the…
Ariceum Therapeutics files for UK Clinical Trial Authorisation (CTA) to test its First-in-Class Iodine-123 labelled PARP inhibitor in patients with recurrent glioblastoma
Berlin, Germany, 10th January 2024 – Ariceum Therapeutics,…
Novo Nordisk Foundation partners with CARB-X to fight drug-resistant infections
COPENHAGEN, Denmark, Jan. 9, 2024 - The Novo Nordisk Foundation…
Futura Medical plc – Appointment of Roy Davis as Non-Executive Director
Futura Medical plc (AIM: FUM) ("Futura" or the "Company"), the…
Revagenix, Inc. Announces Series B Financing to Develop Novel Antibiotics and Additions to its Board of Directors
Tenmile and Novo Holdings are…
2023 Novo Holdings Seed Investments Team Annual Review/Business Update
Several significant portfolio financing rounds
Launch…
Biocomposites’ investee Renovos Biologics receives FDA Breakthrough Device Designation for its synthetic nanoclay bone fusion gel, RENOVITE® BMP-2
RENOVITE® BMP-2 is being developed as an alternative to…
Vicore Reports Positive Results for the Pivotal Study of its Digital Therapy for Patients with Pulmonary Fibrosis
The COMPANION pivotal study met the primary endpoint and…
SpliceBio Appoints Leading Ophthalmology Expert Aniz Girach as Chief Medical Officer
Dr. Girach is a world-renowned specialist in the field…
Vicore Confirms IPF Development Program on Track and Provides Early-Stage Pipeline Updates
Development of C21 in IPF on track; final Phase 2a AIR data…
IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket Trial
NEW YORK, December 21, 2023 (GLOBE NEWSWIRE) – IO Biotech (Nasdaq:…
Calliditas Therapeutics announces full FDA approval of TARPEYO®, the only FDA-approved treatment for IgA nephropathy to significantly reduce the loss of kidney function
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX)…
European Commission revokes all centrally granted generic marketing permissions for dimethyl fumarate (“DMF”), including Dimethyl Fumarate Neuraxpharm
Decision is not due to any public health concerns regarding generic…
4SC AG – Company Update
Planegg-Martinsried, Germany, 20 December 2023 – 4SC AG (4SC,…
Poolbeg Pharma plc – Positive Outputs from Lab-Based Analysis of RSV Drug Candidates Identified Using AI
RSV drug candidates with the highest probability of success prioritised
20…
HERVOLUTION Therapeutics Appoints Biotech Builder J. Robert Coleman as CEO to Accelerate Groundbreaking Immunotherapies to Treat Dark Genome Targets in Cancer, Aging, and Neurodegeneration
Copenhagen, Denmark & New York, USA — 19 Dec 2023— HERVOLUTION…
We’d love to hear from you.
For more information about Optimum Strategic Communications, please get in touch.
We are specialists with an indepth understanding of how to communicate complex science to investors and corporate stakeholders. We help companies on their journey as they grow and have been trusted by hundreds of clients from around the world, both public and private, large and small.
Locations
- London
- Amsterdam
- Stockholm
- Zurich
- New York